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ABSTRACT
There is increasing interest concerning the possible impact of anti-tumour necrosis factor (TNF)-a
therapeutic agents on the emergence of infections. However, these agents do not seem to increase the
incidence of adverse infectious events significantly. Published observations concern mostly infections of
the urinary and upper respiratory tracts that develop in the setting of co-morbidities, such as anterior or
concomitant immunosuppressive treatment. Infliximab appears to increase the risk of tuberculosis, but
this effect has not been observed with other anti-TNF-a agents. To better characterise the adverse
infectious effects associated with these agents, physicians should be encouraged to notify the
microbiological data relating to all cases.
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Many patients have been prescribed tumour
necrosis factor (TNF)-a blocking agents to treat
diseases such as rheumatoid arthritis (RA) or
Crohn’s disease [1]. TNF-a is a pro-inflammatory
cytokine that is involved in the immune protection
against infection, and it is therefore possible that
TNF-a neutralisation may favour the development
of infection. Several studies have now reported
data concerning the impact of anti-TNF-a thera-
peutic agents on the emergence of infections.
The ATTRACT study was a multicentre, dou-
ble-blind, randomised and placebo-controlled
trial that evaluated treatment efficacy and toler-
ance in 428 patients who presented with active
RA despite treatment with methotrexate [2]. The
study investigated the incidence of infection in
infliximab-treated patients (26%) in comparison
with patients treated with methotrexate alone
(16%). Most of the infections observed were
upper respiratory and urinary tract infections.
There was no significant difference in the propor-
tion of severe infections that were developed by
infliximab-treated and methotrexate-treated pa-
tients (6% vs. 8%, respectively).
A second double-blind randomised trial includ-
ed 89 patients with active RA despite metho-
trexate treatment [3]. Patients were randomised
into two groups: group A, treated with etanercept
in combination with methotrexate, and group B,
treated with methotrexate alone. The combination
of etanercept with methotrexate did not increase
the incidence of infections, with 51% of patients
in group A and 63% in group B developing
infections (p <0.37). One-third of the infections in
both groups comprised upper respiratory tract
infections.
In the study reported by Bathon et al. [4], 632
patients with recent RA were randomised into
two groups treated with either etanercept or
methotrexate. The numbers of patients who
developed at least one infection were identical
in the two groups. However, the number of
episodes of infection that occurred per patient-
year was significantly higher among patients who
received methotrexate alone in comparison with
those who received etanercept. Infections requir-
ing hospitalisation or intravenous administration
of antibiotics occurred in <3% of the patients in
each group. In the ARMADA trial [5], 271 patients
with active RA were treated with methotrexate
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and adalimumab for 12 months. The infection
rate per patient-year was 0.02 and 0.03 during the
first and second 6-month periods, respectively.
Before the introduction of anti-TNF-a treat-
ment, the incidence of tuberculosis in patients
with RA seemed to be higher in the general
population of Europe than that of the USA.
However, difficulties in the evaluation of inci-
dence data tend to bias the interpretation, first,
because of a frequent absence of notification of
cases of tuberculosis in the USA, and second,
because the high cost of anti-TNF-a treatment in
the USA makes it more accessible for patients
who have a relatively high standard of living, and
consequently a lower risk of developing tubercu-
losis, than individuals with a low standard of
living or those living in countries with a high
incidence of tuberculosis.
Gomez-Reino et al. [6] evaluated the incidence
of tuberculosis among patients treated with anti-
TNF-a agents who were contained in a database
of 1540 patients (86% treated with infliximab and
14% treated with etanercept). Seventeen cases of
tuberculosis were recorded among patients treat-
ed with infliximab. The estimated incidence of
tuberculosis associated with the use of infliximab
in RA patients was 1893 and 1113 per 100 000 in
2000 and 2001, respectively. These data indicate a
significantly increased risk of tuberculosis in
comparison with RA patients who were not
treated with anti-TNF-a agents. However, the
data should be interpreted with caution because
the study was not prospective. For patients
treated with etanercept, 13 cases of tuberculosis
were detected during follow-up of 138 000 pa-
tients (eight cases in the USA). Given the overall
incidence of tuberculosis in the USA, the expected
incidence would have been 11 cases. Thus, etan-
ercept did not seem to increase the incidence of
tuberculosis in the USA [7]. These data also
require cautious interpretation, since the inci-
dence of tuberculosis is notably higher in Europe
than in the USA, and etanercept is used less than
infliximab in Europe. Any difference in risk
attributable to these two agents may reflect their
diversity of effects. No case of tuberculosis was
reported following treatment with adalimumab.
In the study reported by Keane et al. [8], 70
cases of tuberculosis occurred during or after
treatment between 1998 and May 2001. The
median period from the start of treatment to the
onset of tuberculosis was 12 weeks. It is likely that
most patients had reactivation disease, and 70%
of the patients had received immunosuppressive
therapy, which is known to increase the fre-
quency of tuberculosis in RA patients [9]. More
than 56% of the patients had extra-pulmonary
manifestations of tuberculosis, and c. 25% had
disseminated tuberculosis. Taking into account
the apparent risk, international recommendations
for the prevention and follow-up of tuberculosis
in patients treated with infliximab were published
in 2004 [10].
Opportunistic infections may also occur at
increased frequency in patients treated with
anti-TNF-a agents. However, many such infec-
tions are not notified and their frequency is
difficult to evaluate. Among 175 000 patients
treated with infliximab since FDA approval, 42
opportunistic infections have been recorded,
including 11 cases of primary or disseminated
histoplasmosis, six cases of pneumocystis, six
cases of aspergillosis, eight cases of systemic
candidosis, two cases of coccidiomycosis and six
cases of listeriosis. Most of these patients were
also treated with immunosuppressive drugs [11].
In conclusion, the present data do not suggest
that anti-TNF-a treatment increases the incidence
of adverse infectious events significantly. How-
ever, the incidence of infection has not been
evaluated precisely, and data from microbiologi-
cal studies are scarce. Most reported infections
concern the upper respiratory and urinary tracts,
and seem to develop in the setting of anterior or
concomitant immunosuppressive treatment. In-
fliximab increases the risk of tuberculosis by a
mechanism which has not been elucidated, but
this effect has not been observed with other anti-
TNF-a agents. Physicians should be encouraged
to report adverse infectious events associated
with these agents.
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